Moreover, studies have demonstrated that HSCs stimulate the release of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) which upregulates angiogenesis in order to repair liver sinusoids, but during chronic inflammation this process is deregulated and contributes to portal hypertension maintenance since these new vessels are not capable to increase the blood perfusion of hepatocytes, worsening local ischemia [96,109]. Here, VEGFA is linked to liver disorder.